InsiderSignal.AI

InsiderSignal.ai

ALMS - Alumis Inc.

Insider Purchase by Foresite Labs, LLC (10%)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Foresite Labs, LLC, serving as 10% owner at Alumis Inc. (ALMS), purchased 411,764 shares at $17.00 per share, for a total transaction value of $6,999,988.00. Following this transaction, Foresite Labs, LLC now holds 10,487,268 shares of ALMS.

This purchase represents a 4.00% increase in Foresite Labs, LLC's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, January 8, 2026 and publicly disclosed via SEC Form 4 filing on Monday, January 12, 2026, 4 days after the trade was made.

Alumis Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Foresite Labs, LLC

Foresite Labs, LLC

10%

Foresite Labs, LLC is a center for entrepreneurial innovation at the nexus of data science, artificial intelligence, and healthcare, founded in 2019 and headquartered in San Francisco, California, with operations also in Boston.[[1]](https://www.zoominfo.com/c/foresite-labs/480664975)[[2]](https://foresitelabs.com)[[4]](https://foresitelabs.com/about/) The company partners with visionary entrepreneurs to incubate, build, and scale life sciences and healthcare ventures that leverage AI, data science, and advanced analytics to accelerate scientific discovery and address unmet medical needs, including immune-mediated diseases.[[1]](https://www.zoominfo.com/c/foresite-labs/480664975)[[2]](https://foresitelabs.com)[[3]](https://synapse.patsnap.com/organization/add5e0a4f8745d3671e2e6779526403c)[[4]](https://foresitelabs.com/about/) Foresite Labs operates as a biotechnology startup incubator, developing an ecosystem of companies tackling major challenges through AI-driven solutions, with a reported revenue of $14.8 million and 10-50 employees (previously noted as 70).[[1]](https://www.zoominfo.com/c/foresite-labs/480664975)[[3]](https://synapse.patsnap.com/organization/add5e0a4f8745d3671e2e6779526403c)[[5]](https://app.academiclabs.com/organisation/uZQyhk65DpU7)[[6]](https://foresitelabs.com/companies/) As a corporate insider, Foresite Labs has recently engaged in significant transactions with Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company it incubated, holding a notable position such as 10% ownership amid key developments like the acquisition of ACELYRIN's lonigutamab program for thyroid eye disease.[[3]](https://synapse.patsnap.com/organization/add5e0a4f8745d3671e2e6779526403c) Leadership includes key appointments like Ian Tong, MD as Chief Clinical Officer (former Stanford professor), Mary Helen Black as VP and Head of Human Genomics (ex-Johnson & Johnson), and Uplaksh Kumar as COO.[[1]](https://www.zoominfo.com/c/foresite-labs/480664975) Foresite Labs continues to drive innovation by integrating scientific rigor with technology to propel breakthroughs across industries.[[2]](https://foresitelabs.com)[[4]](https://foresitelabs.com/about/)

View full insider profile →

Trade Price

$17.00

Quantity

411,764

Total Value

$6,999,988.00

Shares Owned

10,487,268

Trade Date

Thursday, January 8, 2026

45 days ago

SEC Filing Date

Monday, January 12, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Alumis Inc.

Company Overview

No company information available
View news mentioning ALMS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3054399

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime